Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Net Cash Flow (2020 - 2025)

Historic Net Cash Flow for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to $24.8 million.

  • Lyell Immunopharma's Net Cash Flow rose 17478.57% to $24.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.6 million, marking a year-over-year increase of 11321.77%. This contributed to the annual value of -$38.6 million for FY2024, which is 27488.35% down from last year.
  • Lyell Immunopharma's Net Cash Flow amounted to $24.8 million in Q3 2025, which was up 17478.57% from -$21.6 million recorded in Q2 2025.
  • In the past 5 years, Lyell Immunopharma's Net Cash Flow ranged from a high of $320.1 million in Q2 2021 and a low of -$170.9 million during Q3 2021
  • In the last 5 years, Lyell Immunopharma's Net Cash Flow had a median value of -$14.1 million in 2023 and averaged -$826947.4.
  • Data for Lyell Immunopharma's Net Cash Flow shows a peak YoY increase of 78189.48% (in 2023) and a maximum YoY decrease of 204044.73% (in 2023) over the last 5 years.
  • Quarter analysis of 5 years shows Lyell Immunopharma's Net Cash Flow stood at -$99.7 million in 2021, then skyrocketed by 107.27% to $7.2 million in 2022, then plummeted by 2040.45% to -$140.6 million in 2023, then soared by 104.77% to $6.7 million in 2024, then soared by 269.73% to $24.8 million in 2025.
  • Its last three reported values are $24.8 million in Q3 2025, -$21.6 million for Q2 2025, and $14.7 million during Q1 2025.